Karo Pharma AB (publ)
KARBFOTCHealthcare
$5.25
+$0.00(+0.00%)
Market Cap$1.5B
P/E Ratio—
52W High$5.70892
52W Low$5.25
Karo Pharma AB (publ) (KARBF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KARBF · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2022Report Date: Feb 25, 2022EPS Actual
-$0.48
Est. $0.23 · -308.7%
Revenue
—
Fiscal Period
Q1 FY2022
FY ends December
Report Date
Feb 25, 2022
After Market Close
▼ Miss EPS
KARBF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2022 | Jul 21, 2022 | $0.02 | — | — | — | — | — |
| ▼ Q1 FY2022 | Feb 25, 2022 | $0.23 | -$0.48 | -308.7% | — | — | — |
| ▲ Q4 FY2021 | Oct 28, 2021 | $0.05 | $0.20 | +300.0% | — | — | — |
| ▼ Q3 FY2021 | Jul 22, 2021 | $0.28 | -$0.10 | -135.7% | — | — | — |
| ▼ Q2 FY2021 | Apr 21, 2021 | $0.55 | $0.24 | -56.4% | — | — | — |
| ▲ Q4 FY2020 | Oct 30, 2020 | $0.44 | $0.66 | +50.0% | — | — | — |
| ▼ Q3 FY2020 | Jul 21, 2020 | $0.49 | $0.17 | -65.3% | — | — | — |
| ◌ Q2 FY2020 | Apr 29, 2020 | — | — | — | — | — | — |
Q3 FY2022
Jul 21, 2022
EPS Actual
—
EPS Est.
$0.02
EPS Surpr.
—
Revenue
—
Q1 FY2022
Feb 25, 2022Miss
EPS Actual
-$0.48
EPS Est.
$0.23
EPS Surpr.
-308.7%
Revenue
—
Q4 FY2021
Oct 28, 2021Beat
EPS Actual
$0.20
EPS Est.
$0.05
EPS Surpr.
+300.0%
Revenue
—
Q3 FY2021
Jul 22, 2021Miss
EPS Actual
-$0.10
EPS Est.
$0.28
EPS Surpr.
-135.7%
Revenue
—
Q2 FY2021
Apr 21, 2021Miss
EPS Actual
$0.24
EPS Est.
$0.55
EPS Surpr.
-56.4%
Revenue
—
Q4 FY2020
Oct 30, 2020Beat
EPS Actual
$0.66
EPS Est.
$0.44
EPS Surpr.
+50.0%
Revenue
—
Q3 FY2020
Jul 21, 2020Miss
EPS Actual
$0.17
EPS Est.
$0.49
EPS Surpr.
-65.3%
Revenue
—
Q2 FY2020
Apr 29, 2020
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
No analyst estimates available for KARBF.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2022 | Feb 25, 2022 | -308.7% | $5.76 | $5.76 | +0.00% |
| ▲ Q4 FY2021 | Oct 28, 2021 | +300.0% | $5.76 | $5.76 | +0.00% |
| ▼ Q3 FY2021 | Jul 22, 2021 | -135.7% | $5.76 | $5.76 | +0.00% |
| ▼ Q2 FY2021 | Apr 21, 2021 | -56.4% | $5.76 | $5.76 | +0.00% |
| ▲ Q4 FY2020 | Oct 30, 2020 | +50.0% | $6.31 | $6.31 | +0.00% |
| ▼ Q3 FY2020 | Jul 21, 2020 | -65.3% | $6.31 | $6.31 | +0.00% |
| — Q4 FY2019 | Nov 15, 2019 | — | $4.01 | $4.01 | +0.00% |
| ▼ Q3 FY2019 | Jul 19, 2019 | -63.8% | $4.01 | $4.01 | +0.00% |
Q1 FY2022+0.00%
Report Date
Feb 25, 2022
EPS Beat/Miss
-308.7%
Price Before
$5.76
Price After
$5.76
Q4 FY2021+0.00%
Report Date
Oct 28, 2021
EPS Beat/Miss
+300.0%
Price Before
$5.76
Price After
$5.76
Q3 FY2021+0.00%
Report Date
Jul 22, 2021
EPS Beat/Miss
-135.7%
Price Before
$5.76
Price After
$5.76
Q2 FY2021+0.00%
Report Date
Apr 21, 2021
EPS Beat/Miss
-56.4%
Price Before
$5.76
Price After
$5.76
Q4 FY2020+0.00%
Report Date
Oct 30, 2020
EPS Beat/Miss
+50.0%
Price Before
$6.31
Price After
$6.31
Q3 FY2020+0.00%
Report Date
Jul 21, 2020
EPS Beat/Miss
-65.3%
Price Before
$6.31
Price After
$6.31
Q4 FY2019+0.00%
Report Date
Nov 15, 2019
EPS Beat/Miss
—
Price Before
$4.01
Price After
$4.01
Q3 FY2019+0.00%
Report Date
Jul 19, 2019
EPS Beat/Miss
-63.8%
Price Before
$4.01
Price After
$4.01
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate2 / 8 quarters
Largest Move+0.00% (Q1 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KARBF ends December
Karo Pharma AB (publ) (KARBF) most recently reported earnings on February 25, 2022 for Q1 FY2022, posting EPS of $-0.48 — missing the analyst consensus of $0.23 by -308.7%. The next KARBF earnings date is expected around September 1, 2026.
Each quarter, investors track KARBF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KARBF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KARBF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KARBF earnings · 5 questionsKaro Pharma AB (publ)'s next earnings report is expected around September 1, 2026. KARBF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KARBF historically reports after market close (AMC).
KARBF earnings datewhen is KARBF earningsKARBF next earnings datewhen does KARBF report earningsKARBF earnings calendar
▸ Source: FMP · Karo Pharma AB (publ) SEC filings · US GAAP · Karo Pharma AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026